Advanced glycosylated end-products (AGEs) in non-diabetic patients undergoing dialysis.

R. Brunkhorst(Klinikum Region Hannover), A. Mahiout(Medizinische Hochschule Hannover), Marcelo Lapa Kruse, G. Ehlerding(Medizinische Hochschule Hannover)

PubMed

October 1, 1996

Cited by 2

Related Papers

Epidemiology of sepsis in Germany: results from a national prospective multicenter study

|Intensive Care Medicine|2007|623

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

|BMJ|2012|309

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

|Journal of the American Society of Nephrology|2002|274

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study

|Arthritis & Rheumatism|1998|261

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry

|Nephrology Dialysis Transplantation|2012|239